Clinical trials: Single Dose
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy…
- Trial name
- NCT01607762
- Testing
- Aripiprazole, Quetiapine, Olanzapine
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Safety Study of LY3041658 in Healthy Participants
The main purpose of this study is to evaluate the safety of LY3041658 in healthy participants, including first generation Japanese. The study will also investigate how the drug is processed and affects key immune cells.
- Trial name
- NCT02148627
- Testing
- LY3041658 (SC), LY3041658 (IV)
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Osteoarthritis
First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the Knee
Primary Objective: To assess the safety and tolerability of ascending single intraarticular doses of GZ389988 in patients with painful osteoarthritis (OA) of the knee.
- Trial name
- NCT02424942
- Testing
- GZ389988
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Genzyme, a Sanofi Company
Meningococcal Infection (Healthy Volunteers)
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Primary Objective: To demonstrate sufficiency of the vaccine seroresponse to meningococcal serogroups A, C, W, and Y following administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135)…
- Trial name
- NCT04142242
- Testing
- Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules (AstraZeneca Sweden, Product of France)
Comparative randomized, single dose Bioequivalence Study of Esomeprazole From Stomopral 40 mg Capsules Contain Enteric Coated Pellets (Future Pharmaceuticals Industries, Egypt) and Nexium 40 mg Delayed Release Capsules…
- Trial name
- NCT05038969
- Testing
- Stomopral, Nexium
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Diarrhea
Study to Compare the Pharmacokinetics Profiles of Four Racecadotril Products
This study is designed to compare the pharmacokinetics of four products used for treatment of acute diarrhea.
- Trial name
- NCT01476683
- Testing
- Racecadotril
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McNeil AB
Non-small Cell Lung Cancer, Brain Metastases
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.
- Trial name
- NCT01516983
- Testing
- icotinib, Whole brain radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Multiple Myeloma
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
- Trial name
- NCT05722405
- Testing
- Ixazomib plus low-dose lenalidomide, Ixazomib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Obstructive Pulmonary Disease (COPD), Asthma
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
AZD7594 is a non steroidal, potent and selective modulator of the glucocorticoid receptor (GR) under development for once daily inhaled treatment of chronic obstructive pulmonary disease (COPD) and asthma.
- Trial name
- NCT02967159
- Testing
- Abediterol, AZD7594, AZD7594/abediterol
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib
This study is an open-label, absorption, metabolism, excretion, and mass balance study of 400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose to 6 healthy male subjects following at…
- Trial name
- NCT02803762
- Testing
- Pacritinib
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Healthy
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
- Trial name
- NCT06612970
- Testing
- HB0056
- Where
- New Zealand
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.
- Trial name
- NCT07647783
- Testing
- SYH2072 Tablets
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- InnovStone Therapeutics Limited
Healthy
Bioequivalence Study of Simvastatin Tablets 80 mg of Dr. Reddy's Under Fasting Condition
The purpose of this study is to compare the single dose bioavailability of Simvastatin 80 mg tablets with Zocor® 80 mg tablets of MercK \& Co.
- Trial name
- NCT01167894
- Testing
- Simvastatin
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Healthy
Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
This study investigated the bioequivalence of the 100 milligrams (mg) and 250 mg dose strengths of tepotinib tablet formulation 3 (TF3) when administered at the same dose under fasted condition.
- Trial name
- NCT04204902
- Testing
- Tepotinib 100 mg, Tepotinib 250 mg
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Metabolic Dysfunction-Associated Steatohepatitis
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers in Parts A, B, D and F and in participants with a…
- Trial name
- NCT05945537
- Testing
- INI-822 (A)
- Where
- 11 sites in Australia
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Inipharm Australia Pty Ltd
Healthy
A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects
This is an open-label study investigating the relationship between SEP-228432 and SEP-228431 (the active metabolite of SEP-228432) plasma concentrations, SERT occupancy, and DAT occupancy, both measured by SPECT imaging.
- Trial name
- NCT01531972
- Testing
- SEP-228432
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Spastic Cerebral Palsy
INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
Prospective, open-label, non-randomized, single-arm, dose titration, phase II study. The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks.
- Trial name
- INCIPIT (NCT05340439)
- Testing
- IncobotulinumtoxinA 100 UNT [Xeomin]
- Volunteers
- 30 people
- Sponsor
- Universita di Verona
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.